Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis
Green, Jessica Emily, Davis, Jessica A., Berk, Michael, Hair, Christopher, Loughman, Amy, Castle, David, Athan, Eugene, Nierenberg, Andrew A., Cryan, John F., Jacka, Felice, and Marx, Wolfgang (2020) Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis. Gut Microbes, 12 (1). 1854640.
|
PDF (Published Version)
- Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
The intestinal microbiome has been identified as a key modifier for a variety of health conditions. Fecal Microbiota Transplantation (FMT) has emerged as a fast, safe, and effective means by which to modify the intestinal microbiome and potentially treat a variety of health conditions. Despite extensive research of FMT for CDI, there is a lack of clarity informed by systematic synthesis of data regarding the safety and efficacy of FMT for other health conditions. This systematic review used PRISMA guidelines and was prospectively registered with PROSPERO (CRD42018104243). In March 2020, a search of MEDLINE, EMBASE, and PsycINFO was conducted. We identified 26 eligible studies. A meta-analysis of FMT for active Ulcerative Colitis (UC) showed that FMT significantly improved rates of clinical remission (OR = 3.634, 95% CI = 1.940 to 6.808, I-2 = 0%, p < .001), clinical response (OR = 2.634, 95% CI = 1.441 to 4.815, I-2 = 33%, p = .002) and endoscopic remission (OR = 4.431, 95% CI = 1.901 to 10.324, I-2 = 0%, p = .001). With respect to Irritable Bowel Syndrome, a meta-analysis showed no significant change in symptoms following FMT (p = .739). Hepatic disorders, metabolic syndrome, and antibiotic-resistant organisms were conditions with emerging data on FMT. Serious adverse events (AE) were more often reported in control group participants (n = 43) compared with FMT group participants (n = 26). There were similar rates of mild to moderate AE in both groups. Preliminary data suggest that FMT is a potentially safe, well-tolerated and efficacious treatment for certain conditions other than CDI, with evidence for active UC being the most compelling.
| Item ID: | 66192 |
|---|---|
| Item Type: | Article (Research - C1) |
| ISSN: | 1949-0984 |
| Keywords: | Fecal microbiota transplantation, clostridium difficile, microbiome, meta-analysis, RCT, systematic review, ulcerative colitis, irritable bowel syndrome, psychiatry, mental disorder, neuroscience, depression |
| Copyright Information: | © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Date Deposited: | 13 Jan 2021 07:47 |
| FoR Codes: | 31 BIOLOGICAL SCIENCES > 3107 Microbiology > 310701 Bacteriology @ 100% |
| Downloads: |
Total: 979 Last 12 Months: 109 |
| More Statistics |
Actions (Repository Staff Only)
 |
Item Control Page |